REGN
REGENERON PHARMACEUTICALS, INC.
$635.45
+1.07%
$65.9B
No data for this timeframe.
Vol
Market Cap$65.9B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (71%)
Inst. Holders11 funds
Inst. Value$16.4B
Inst. Activity2 buys / 2 sells
Insider Activity0B / 6S
Insider Net $-$64.0K
Reddit Sentiment67° Warm
SEC Reports6
Press Releases8
Congressional2 trades
Recent Activity
Aug 1, 2026
fda_pdufa
PDUFA: REGN — garetosmab in fibrodysplasia ossificans progressiva (FOP) — 2026-08-01
FDA target action date 2026-08-01 for REGN (REGENERON PHARMACEUTICALS, INC.). Drug: garetosmab. Indi
May 31, 2026
SEC
11 firms acted on REGN: Barclays, B of A Securities, Morgan Stanley, HSBC, Wells Fargo, Citigroup, Leerink Partners, UBS, Wolfe Research, Citigroup, Leerink Partners
ANALYST-UPGRADE — Impact 3/10
May 21, 2026
Press
Regeneron announced positive Phase 1/2 LINKER-AL2 results for Lynozyfic (linvoseltamab) in second-line-plus systemic AL
Impact 6/10
May 18, 2026
SEC
Citigroup and Leerink Partners downgrade REGN to Neutral/Market Perform — PTs slashed to $700/$641; stock near PT levels
ANALYST-DOWNGRADE — Impact 2/10
May 18, 2026
Press
Regeneron announced a strategic research collaboration with Parabilis Medicines to discover Antibody-Helicon Conjugates
Impact 4/10
May 1, 2026
SEC
BofA upgrades REGN to Buy from Underperform — PT $860 (+22%)
ANALYST-UPGRADE — Impact 4/10
May 1, 2026
Insider
RYAN ARTHUR F sold 5 shares
Director @ $701.76 ($3.5K)
Apr 2, 2026
Event
EYLEA HD
Supplemental Approval — Efficacy — AFLIBERCEPT — INJECTABLE — INTRAVITREAL
Price Targets
$833.31
+31.1% upside
Strong Buy
Current $635.45
Low $641.00
Median $852.50
High $1,000.00
28 analysts
$641.00
$1,000.00
Analyst Ratings
9Strong Buy
18Buy
11Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 19, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| May 18, 2026 | BMO Capital | MAINTAIN | Outperform → Outperform |
| May 18, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| May 18, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| May 18, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $10.85 | $8.27 — $13.25 | -16% YoY | 23 |
| Next Q | $13.08 ▲ +0.6% | $8.88 — $17.10 | 11% YoY | 23 |
| Current FY | $46.25 | $37.15 — $53.61 | 4% YoY | 29 |
| Next FY | $48.10 | $40.93 — $60.05 | 25% YoY | 10 |
Latest Reports
BULLISH
Press
6/10
Regeneron announced positive Phase 1/2 LINKER-AL2 results for Lynozyfic (linvoseltamab) in second-line-plus systemic AL
May 21, 2026
BEARISH
ANALYST-DOWNGRADE
2/10
Citigroup and Leerink Partners downgrade REGN to Neutral/Market Perform — PTs slashed to $700/$641; stock near PT levels
May 18, 2026
BULLISH
ANALYST-UPGRADE
4/10
BofA upgrades REGN to Buy from Underperform — PT $860 (+22%)
May 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $7.0B | — |
| DODGE & COX | $3.5B | ADD |
| FMR LLC | $1.8B | TRIM |
| MORGAN STANLEY | $1.1B | — |
| NORGES BANK | $1.0B | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | RYAN ARTHUR | SELL | $3.5K |
| Apr 1, 2026 | RYAN ARTHUR | SELL | $771.32 |
| Mar 2, 2026 | RYAN ARTHUR | SELL | $5.4K |
| Feb 19, 2026 | Zoghbi Huda | M | $617.0K |
| Feb 19, 2026 | Zoghbi Huda | SELL | $38.0K |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
Congressional Trades
2 members: 2 buys, 0 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Ro Khanna | D | BUY | $1,001 - $15,000 |
| Julia Letlow | R | BUY | $1,001 - $15,000 |
11 institutional holders with $16.4B total value (21,233,481 shares) as of 2025-Q4. Top holders: VANGUARD, DODGE, FMR.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 9,075,153 | $7.0B | 42.7% | — |
| 2 | DODGE & COX | 4,596,358 | $3.5B | 21.6% | ADD +64.6% |
| 3 | FMR LLC | 2,319,566 | $1.8B | 10.9% | TRIM -41.8% |
| 4 | MORGAN STANLEY | 1,389,323 | $1.1B | 6.5% | — |
| 5 | NORGES BANK | 1,311,485 | $1.0B | 6.2% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 1,157,426 | $893.4M | 5.5% | — |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 778,001 | $600.5M | 3.7% | NEW |
| 8 | TWO SIGMA INVESTMENTS, LP | 281,151 | $217.0M | 1.3% | TRIM -40.2% |
| 9 | SOUND SHORE MANAGEMENT INC /CT/ | 175,887 | $135.8M | 0.8% | ADD +52.9% |
| 10 | WELLS FARGO & COMPANY/MN | 140,049 | $108.1M | 0.7% | — |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 9,082 | $7.0M | 0.0% | NEAR_EXIT -96.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 1,311,485 | — | $1.0B | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 469,903 | 281,151 | -40.2% | $217.0M | 2025-Q4 |
| SOUND SHORE MANAGEMENT INC /CT/ | ADD | 115,028 | 175,887 | +52.9% | $135.8M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 275,162 | 9,082 | -96.7% | $7.0M | 2025-Q4 |
| FMR LLC | TRIM | 3,327,051 | 1,935,835 | -41.8% | $1.1B | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 45,062 | 275,162 | +510.6% | $154.7M | 2025-Q3 |
| SOUND SHORE MANAGEMENT INC /CT/ | NEW | — | 115,028 | — | $64.7M | 2025-Q3 |
| NORGES BANK | EXIT | 1,196,479 | 0 | -100.0% | $0.00 | 2025-Q3 |
| DODGE & COX | ADD | 2,324,085 | 3,826,283 | +64.6% | $2.0B | 2025-Q2 |
| FMR LLC | TRIM | 7,598,584 | 3,327,051 | -56.2% | $1.7B | 2025-Q2 |
| NORGES BANK | NEW | — | 1,196,479 | — | $628.2M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | ADD | 372,071 | 499,828 | +34.3% | $262.4M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 78,901 | 45,062 | -42.9% | $23.7M | 2025-Q2 |
| UBS Group AG | TRIM | 578,035 | 376,263 | -34.9% | $238.6M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 34,543 | 372,071 | +977.1% | $236.0M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 247,743 | 78,901 | -68.2% | $50.0M | 2025-Q1 |
| NORGES BANK | EXIT | 1,125,933 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | ADD | 446,250 | 578,035 | +29.5% | $411.8M | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 416,560 | 568,246 | +36.4% | $404.8M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 673,261 | — | $707.8M | 2024-Q3 |
3 unique insiders with 6 transactions. Net insider value: -$64.0K ($0.00 bought, $64.0K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | RYAN ARTHUR F | Director | SELL | 5 | $701.76 | $3.5K |
| Apr 1, 2026 | RYAN ARTHUR F | Director | SELL | 1 | $771.32 | $771.32 |
| Mar 2, 2026 | RYAN ARTHUR F | Director | SELL | 7 | $777.46 | $5.4K |
| Feb 19, 2026 | Zoghbi Huda Y | Director | M | 1,638 | $376.69 | $617.0K |
| Feb 19, 2026 | Zoghbi Huda Y | Director | SELL | 49 | $774.68 | $38.0K |
| Feb 19, 2026 | Zoghbi Huda Y | Director | M | 1,638 | $0.00 | $0.00 |
| Feb 9, 2026 | Pitofsky Jason | SVP Controller | M | 1,000 | $0.00 | $0.00 |
| Feb 9, 2026 | Pitofsky Jason | SVP Controller | M | 1,000 | $492.00 | $492.0K |
| Feb 9, 2026 | Pitofsky Jason | SVP Controller | SELL | 20 | $775.95 | $15.5K |
| Feb 9, 2026 | RYAN ARTHUR F | Director | SELL | 1 | $775.63 | $775.63 |
6 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 3.2/10.
BULLISH
ANALYST-UPGRADE
4/10
BofA upgrades REGN to Buy from Underperform — PT $860 (+22%)
May 1, 2026
BEARISH
ANALYST-DOWNGRADE
2/10
Citigroup and Leerink Partners downgrade REGN to Neutral/Market Perform — PTs slashed to $700/$641; stock near PT levels
May 18, 2026
BULLISH
ANALYST-UPGRADE
3/10
11 firms acted on REGN: Barclays, B of A Securities, Morgan Stanley, HSBC, Wells Fargo, Citigroup, Leerink Partners, UBS, Wolfe Research, Citigroup, Leerink Partners
May 31, 2026
NEUTRAL
DEFA14A
3/10
Regeneron Pharmaceuticals has filed definitive additional proxy soliciting materials (DEFA14A) with
Apr 24, 2026
NEUTRAL
8-K
4/10
Regeneron Pharmaceuticals expects a $102 million acquired in-process R&D charge in Q1 2026, which wi
Apr 21, 2026
NEUTRAL
COURT-RULING
3/10
Analysis based on filing metadata only — document content was unavailable. The case 'Fraioli v. Rege
Mar 30, 2026
BULLISH
6/10
Regeneron announced positive Phase 1/2 LINKER-AL2 results for Lynozyfic (linvoseltamab) in second-li
May 21, 2026
NEUTRAL
4/10
Regeneron announced a strategic research collaboration with Parabilis Medicines to discover Antibody
May 18, 2026
BEARISH
7/10
Regeneron announced that its Phase 3 trial of fianlimab (LAG-3 inhibitor) plus cemiplimab in first-l
May 16, 2026
NEUTRAL
2/10
Regeneron announced the winners of its 2026 International Science and Engineering Fair (ISEF), award
May 15, 2026
BULLISH
8/10
Regeneron announced positive Phase 3 NIMBLE trial results for cemdisiran, an investigational siRNA t
Apr 21, 2026
BULLISH
7/10
Regeneron and Telix announced a collaboration to co-develop and co-commercialize next-generation rad
Apr 13, 2026
BULLISH
7/10
Regeneron and Sanofi announced European Commission approval of Dupixent for children aged 2 to 11 ye
Apr 13, 2026
NEUTRAL
2/10
Regeneron Pharmaceuticals announced it will release its first quarter 2026 financial results on Apri
Mar 25, 2026
Current analyst consensus: Buy (71% buy). Based on 38 analysts: 9 strong buy, 18 buy, 11 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$833.31 mean target
+31.1% upside
Strong Buy (1.72)
$641.00 Low
$1,000.00 High
| Metric | Value |
|---|---|
| Current Price | $635.45 |
| Target Low | $641.00 |
| Target Mean | $833.31 |
| Target Median | $852.50 |
| Target High | $1,000.00 |
| # Analysts | 28 |
| Recommendation | Strong Buy (1.72) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$10.85 | $8.27 | $13.25 | -15.8% | -0.3% | 9↑ 11↓ | $3.8B | 3.8% | 23 |
| Next Q 2026-09-30 |
$13.08 | $8.88 | $17.10 | 10.6% | +0.6% | 13↑ 6↓ | $4.2B | 11.5% | 23 |
| Current FY 2026-12-31 |
$46.25 | $37.15 | $53.61 | 4.4% | -0.3% | 17↑ 8↓ | $15.9B | 10.7% | 29 |
| Next FY 2027-12-31 |
$48.10 | $40.93 | $60.05 | 24.5% | +0.1% | 5↑ 4↓ | $17.6B | 10.5% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $10.852 | |
| 7d ago | $10.852 | |
| 30d ago | $10.885 | -0.033 |
| 60d ago | $10.583 | +0.270 |
| 90d ago | $10.668 | +0.185 |
18 analyst firms have rated this stock: 1 upgrades, 2 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 19, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 18, 2026 | BMO Capital | MAINTAIN | Outperform | Outperform |
| May 18, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| May 18, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| May 18, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| May 18, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| May 18, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| May 18, 2026 | Citigroup | DOWNGRADE | Buy | Neutral |
| May 18, 2026 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
| May 1, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Apr 30, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| Apr 30, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 30, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Apr 30, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 23, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Apr 23, 2026 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 8, 2026 | Bernstein | MAINTAIN | Outperform | Outperform |
| Mar 31, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Mar 6, 2026 | Barclays | INITIATE | — | Overweight |
| Mar 2, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| Feb 9, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Feb 2, 2026 | Oppenheimer | REITERATE | Outperform | Outperform |
| Feb 2, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 2, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 2, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Feb 2, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 22, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Jan 8, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 7, 2026 | B of A Securities | UPGRADE | Underperform | Buy |
| Dec 12, 2025 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Dec 10, 2025 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 18 | 11 | 0 | 0 | 71% | |
| May 1, 2026 | 11 | 19 | 8 | 0 | 0 | 79% | |
| Apr 1, 2026 | 11 | 19 | 8 | 0 | 0 | 79% | |
| Mar 1, 2026 | 11 | 16 | 9 | 0 | 0 | 75% | |
| Feb 1, 2026 | 11 | 16 | 9 | 0 | 0 | 75% | |
| Jan 1, 2026 | 10 | 16 | 9 | 1 | 0 | 72% | |
| Dec 1, 2025 | 10 | 17 | 8 | 1 | 0 | 75% | |
| Nov 1, 2025 | 10 | 16 | 7 | 1 | 0 | 76% |
Strong BuyBuyHoldSellStrong Sell
2 members of Congress traded this stock: 2 buys, 0 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | Regeneron Pharmaceuticals Inc | May 13, 2026 (31d) |
| Feb 12, 2026 | Julia Letlow | R | HOUSE | BUY | $1,001 - $15,000 | Regeneron Pharmaceuticals Inc | Mar 13, 2026 (30d) |
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 25, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Aug 1, 2026
fda_pdufa
PDUFA: REGN — garetosmab in fibrodysplasia ossificans progressiva (FOP) — 2026-08-01
FDA target action date 2026-08-01 for REGN (REGENERON PHARMACEUTICALS, INC.). Drug: garetosmab. Indication: fibrodysplasia ossificans progressiva (FOP
Jul 30, 2026
earnings_calendar
REGN Q2 2026 Earnings After Market Close — 2026-07-30
EPS est: $10.92 | Rev est: $3.9B
May 29, 2026
Clinical Trial
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Phase Phase 3 — COMPLETED
May 28, 2026
other
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
<p><strong><em>Inmazeb</em></strong><sup><strong><em>®</em></strong></sup> <strong><em>(a three-antibody cocktail consisting of maftivimab, atoltivima
May 28, 2026
Clinical Trial
A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants
Phase Phase 2 — COMPLETED
May 22, 2026
other
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
<p>TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (E
May 21, 2026
fda
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
<p><strong>Normalization of free light chains occurred by day 15 across all doses</strong></p>
May 21, 2026
Clinical Trial
A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension
Phase Phase 2 — COMPLETED
May 18, 2026
contract
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
<p align="center"><em>The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptid
May 16, 2026
fda
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
<p><strong>The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)</strong></p>
May 15, 2026
contract
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
May 13, 2026
Clinical Trial
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
Phase Phase 2 — COMPLETED
May 13, 2026
clinical_trial_readout
Results Pending: REGN9933 (Phase 2) — Completed 47d ago
Trial: A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inser
May 13, 2026
short_interest
FTD: REGN — 1,542 shares ($1.1M) failed to deliver
Settlement: 20260513, Price: $723.41, FTD Value: $1,115,498.22, REGENERON PHARMACEUTICALS INC
May 11, 2026
dark_pool
Dark Pool: REGN — 1.1M shares, 43,659 trades
Week starting 2026-05-11. Total ATS volume: 1,071,499 shares across 43,659 trades.
May 8, 2026
Clinical Trial
A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy
Phase Phase 3 — COMPLETED
May 8, 2026
other
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
<p><em>Regeneron also earns spot on Dow Jones Best-in-Class North America Index for six consecutive years</em></p>
May 4, 2026
dark_pool
Dark Pool: REGN — 0.8M shares, 41,999 trades
Week starting 2026-05-04. Total ATS volume: 823,054 shares across 41,999 trades.
Apr 29, 2026
earnings
Regeneron Reports First Quarter 2026 Financial and Operating Results
<p>TARRYTOWN, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:<strong> REGN</strong>) today announced financial res
Apr 29, 2026
earnings_calendar
REGN Q1 2026 Earnings Scheduled — 2026-04-29
Apr 2, 2026
FDA
EYLEA HD
Supplemental Approval — Efficacy — AFLIBERCEPT — INJECTABLE — INTRAVITREAL
Mar 30, 2026
Enforcement
1:26-cv-20636 Fraioli v. Regeneron Pharmaceuticals, Inc. et al
Court ruling from United States District Court for the Southern District of Florida. Docket: N/A